Clinical trial NCT04848714 - References

Latrodectism — Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions

Citation(s)

•   Dart RC, Bush SP, Heard K, Arnold TC, Sutter M, Campagne D, Holstege CP, Seifert SA, Lo JCY, Quan D, Borron S, Meurer DA, Burnham RI, McNally J, Garcia-Ubbelohde W, Anderson VE
  The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')(2) Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med. 2019 Sep;74(3):439-449. doi: 10.1016/j.annemergmed.2019.02.007. Epub 2019 Mar 27.
•   Offerman SR, Daubert GP, Clark RF
  The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series. Perm J. 2011 Summer;15(3):76-81.
•   Ryan NM, Buckley NA, Graudins A
  Treatments for Latrodectism-A Systematic Review on Their Clinical Effectiveness. Toxins (Basel). 2017 Apr 21;9(4). pii: E148. doi: 10.3390/toxins9040148. Review.
•   Vázquez H, Chávez-Haro A, García-Ubbelohde W, Mancilla-Nava R, Paniagua-Solís J, Alagón A, Sevcik C
  Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers. Toxicon. 2005 Dec 1;46(7):797-805. Epub 2005 Sep 28.

Pharmacokinetic Study of ANAWIDOW [Antivenin Latrodectus (Black Widow) Equine Immune F(ab´)2] Solution 10 mL for Intravenous Use of Laboratorios Silanes, S.A. de C.V. in Healthy Adult Male and Female Subjects Under Fasting Conditions.

Details for clinical trial NCT04848714